Ethris GmbH
Semmelweisstr. 3
Planegg
82152
Germany
Tel: 49-0-89-89-55-788-0
Fax: 49-0-89-89-55-788-18
Website: http://ethris.com/
Email: info@ethris.com
About Ethris GmbH
Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.SNIM® RNA is a first-in-class biopharmaceutical platform for therapies of rare diseases, alternative for recombinant proteins, and for “Transcript Therapies” in regenerative medicine. ethris enabling therapies provide access to highly profitable markets.
Ethris was founded at the end of 2009 by Dr. Carsten Rudolph (CEO) and Prof. Dr. Christian Plank (CSO) and was later joined by Dr. Walter Schmidt. The goal of ethris is to rapidly and continuously translate its world-wide unique expertise into clinical trials.
YEAR FOUNDED:
2009
LEADERSHIP:
CEO: Carsten Rudolph
CSO: Christian Plank
19 articles about Ethris GmbH
-
Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-Induced Asthma
12/18/2023
Ethris GmbH announced the dosing of the first healthy participant in its first-in-human study of lead candidate ETH47, which was developed using Ethris’ Stabilized Non-Immunogenic mRNA platform and encodes for type III interferon that plays a vital role in early antiviral response.
-
Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections
11/28/2023
Ethris GmbH announced that it has received approval from the United Kingdom Medicines and Healthcare products Regulatory Agency to proceed with a Phase 1 clinical trial for its inhaled mRNA program, ETH47, in healthy participants for the treatment and prophylaxis of respiratory viral infections.
-
Ethris and Heqet Therapeutics Announce Collaboration to Develop RNA-based Therapeutics for Heart Attack and Heart Failure
11/13/2023
Ethris GmbH and Heqet Therapeutics announced a collaboration agreement to harness the potential of ncRNA for heart tissue regeneration following acute myocardial infarction and in heart failure.
-
Ethris Joins Alliance for mRNA Medicines as a Founding Member
11/1/2023
Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA therapeutics and vaccines, announced it will be a founding member of a new global organization called Alliance for mRNA Medicines.
-
DIOSynVax and Ethris Publish Preclinical Proof of Concept for Their Broadly Protective Vaccine Technologies in Nature Biomedical Engineering
9/25/2023
Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, and DIOSynVax, a Cambridge UK based clinical stage biotech spinout specialized in the development of multi-valent vaccine antigen payloads (VAPs), announced today the publication of preclinical proof of concept results for each of their platform technologies in Nature Biomedical Engineering.
-
Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Betacoronaviruses
12/21/2022
Ethris GmbH announced a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle and stabilisation platforms.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Ethris Raises $26.3 Million Series B to Advance Pipeline of mRNA-based Therapeutics for Respiratory Diseases
2/1/2022
Ethris GmbH, a leading biotechnology company pioneering transformative messenger RNA therapeutics, announced that it has raised $26.3 Million in a Series B financing round led by Laureus Capital.
-
Ethris Receives “Most Innovative Product Top 3” Award for COVID-19 Therapeutic Candidate at 22nd Pharma Trend Image & Innovation Award
9/15/2021
Ethris GmbH announced that its lead COVID-19 therapeutic candidate, ETH47, has been awarded "Most Innovative Product Top 3" in the category of Leap Innovations at the Pharma Trend Image & Innovation Awards 2021.
-
Data coming in about the COVID-19 pandemic shows some promising overall trends, with other more disturbing ones, particularly in breakthrough infections of the fully vaccinated.
-
Ethris Announces Positive Scientific Review of its mRNA-Based COVID-19 Therapeutic Program Application to Bavarian BayTherapie2020 Grant Program
3/30/2021
Funding will advance Ethris’ development of an mRNA-based therapeutic to treat SARS-CoV-2 and its variants
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
-
Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of COVID-19
4/1/2020
Neurimmune AG and Ethris GmbH announced an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of COVID-19.
-
Ethris and Munster University Hospital Receive ZIM Grant for Rare Pulmonary Disease Research
10/1/2019
Collaboration with Prof. Heymut Omran’s laboratory aimed at studying the impact of Ethris’ therapeutic mRNA strategy on primary ciliary dyskinesia
-
Ethris Announces Expansion of Leadership Team
6/3/2019
Thomas Langenickel, M.D. appointed to Chief Medical Officer as lead program ETH42 advances toward clinical trials
-
Ethris Announces Leadership Team Update
12/11/2018
Change in Responsibilities Reflects Growth and Transition to Development Activities
-
AstraZeneca PLC Jumps Deeper Into mRNA Drugs With Ethris Deal
8/21/2017
-
ethris Adds Three New Members To Its Board Of Directors
7/20/2016
-
ethris Adds Three New Members To Its Board Of Directors
7/19/2016